HR-POSITIVE, HER2-NEGATIVE ADVANCED BREAST CANCER
Clinical trials for HR-POSITIVE, HER2-NEGATIVE ADVANCED BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new HR-POSITIVE, HER2-NEGATIVE ADVANCED BREAST CANCER trials appear
Sign up with your email to follow new studies for HR-POSITIVE, HER2-NEGATIVE ADVANCED BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New cancer drug BBO-10203 enters first human trials
Disease control Recruiting nowThis early-stage study tests a new drug called BBO-10203 in people with advanced solid tumors (breast, lung, or colorectal cancer) that have not responded to standard treatments. The drug is designed to block two cancer-driving proteins (PI3K and RAS). Researchers will check safe…
Matched conditions: HR-POSITIVE, HER2-NEGATIVE ADVANCED BREAST CANCER
Phase: PHASE1 • Sponsor: TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New hope for advanced breast cancer: drug combo trial opens
Disease control Recruiting nowThis study tests a new combination of drugs (L-Ornithine L-Aspartate, N-Acetylcysteine, CDK4/6 inhibitors, and Fulvestrant) in 40 women with HR-positive/HER2-negative advanced breast cancer whose disease got worse after standard therapy. The goal is to see if the combo can shrink…
Matched conditions: HR-POSITIVE, HER2-NEGATIVE ADVANCED BREAST CANCER
Phase: PHASE2 • Sponsor: Fudan University • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New combo aims to outperform current standard in advanced breast cancer
Disease control Recruiting nowThis Phase 3 study tests whether adding the experimental drug gedatolisib to standard hormone therapy and palbociclib can delay cancer growth better than the current standard treatment (hormone therapy plus ribociclib) in people with HR-positive, HER2-negative advanced breast can…
Matched conditions: HR-POSITIVE, HER2-NEGATIVE ADVANCED BREAST CANCER
Phase: PHASE3 • Sponsor: Celcuity Inc • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
New drug combo aims to control advanced breast cancer
Disease control Recruiting nowThis study tests two different doses of the drug dalpiciclib combined with letrozole in 120 women with a specific type of advanced breast cancer (HR-positive, HER2-negative). The goal is to see how long the cancer stays under control and how safe the treatment is. Participants wi…
Matched conditions: HR-POSITIVE, HER2-NEGATIVE ADVANCED BREAST CANCER
Phase: PHASE2 • Sponsor: wanghaibo • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC